Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Kaly finds it much harder to fool people this time

<< Previous

Bullboard Posts

Next >>

Comment by MinimumDamageon Mar 09, 2021 2:44pm

119 Views

Post# 32754464

RE:Kaly finds it much harder to fool people this time

The new approach is leaning towards building up the new Avengers or the Justice League association to get Claritas out of it's infancy stage start-up. Now let's see here, will Bob have enough power to spin webs and throw enough Bat-gadget traps to get this going?

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading